Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Visit old site
Home Print this page Email this page Small font size Default font size Increase font size
Users Online: 5202
ORIGINAL ARTICLE
Year : 2016  |  Volume : 8  |  Issue : 2  |  Page : 106-113

Evaluation series on safety and efficacy of nutritional supplements in newly diagnosed hyperglycemia: A placebo-controlled, randomized study


1 Bhatia Hospital, Mumbai, Maharashtra, India
2 St. John's Medical College Hospital, Bangalore, Karnataka, India
3 TOTALL Diabetes Hormone Institute, Indore, Madhya Pradesh, India
4 Bharti Hospital and B.R.I.D.E., Karnal, Harayana, India
5 Inamdar Multispeciality Hospital, Pune, Maharashtra, India
6 Dia Care Hospital, Ahmedabad, Gujarat, India
7 Diabetes Care Centre, Jaipur, Rajasthan, India
8 I5 Clinical Research Pvt. Ltd, Chennai, Tamil Nadu, India

Correspondence Address:
Sanjay Kalra
Bharti Hospital, Wazir Chand Road, Karnal - 132 001, Harayana
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1947-2714.177320

Rights and Permissions

Background: Diabetes is endemic with developing economies contributing to the bulk of this pandemic. Despite the evidence of incremental benefit of glycemic control starting early in life, acceptance of and adherence to modern medications remain suboptimal. Aims: To determine the hemoglobin A1c (HbA1c)-lowering efficacy and safety of nutritional supplement, PreCrea ® , in adult Indians with newly diagnosed hyperglycemia. Materials and Methods: Double-blind, randomized study conducted in six diabetes centers in India. A total of 193 treatment-naïve subjects with newly diagnosed hyperglycemia and fasting plasma glucose (FPG) >100 mg/dL were randomized into either PreCrea ® 600 mg (n = 90) or matched placebo (n = 89) capsules twice daily, along with lifestyle modification, for 12 weeks. The main outcomes were changes in HbA1c and FPG levels, attainment of the American Diabetes Association (ADA)-defined goals for HbA1c, and clinical and biochemical measures of safety. Results: At 12 weeks, mean HbA1c in PreCrea ® group reduced by 0.91% compared with 0.08% increase in the placebo group (P < .001). The reductions in the mean FPG at week 4 (P < .001) and week 12 (P = 0.04) were significant compared to the baseline. ADA goal of HbA1c <7% increased from 15.5% at the baseline to 35.6% at week 12 in PreCrea ® subjects. Clinical safety and biochemical safety did not change. Hypoglycemia and weight gain were not observed with PreCrea ® . Conclusions: Nearly 1% point reduction in HbA1c at week 12 with PreCrea ® is comparable with most first-line glucose-lowering drugs. The safety and tolerability of PreCrea ® highlights its potential as a first-line therapy in newly detected hyperglycemia.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1535    
    Printed29    
    Emailed0    
    PDF Downloaded253    
    Comments [Add]    

Recommend this journal